Press release
Primary Catalyst Driving Unresectable Hepatocellular Carcinoma Market Share Evolution in 2025: The Rising Prevalence Of Liver Cancer Propels Growth In The Unresectable Hepatocellular Carcinoma Market Share Driver
Unresectable Hepatocellular Carcinoma Market Share
The surge in liver cancer occurrences contributes to the expansion of the unresectable hepatocellular carcinoma market. Liver cancer is caused by tumor cells overtaking the healthy, functioning liver cells and proliferating out of control. Liver transplantation and radiofrequency ablation are typical treatments for unresectable hepatocellular carcinoma. For example, the Journal of Hepatology, a Swiss peer-reviewed scientific journal, reported in October 2022 that around 830,200 people worldwide died of liver cancer by 2020. Additionally, there are possibly going to be 1.4 million fresh liver cancer cases diagnosed from 2020 to 2040, a 55.0% yearly increase in new cases. Further, the American Cancer Society, a non-profit organization based in the US, predicted in January 2024 that roughly 41,630 new instances of primary liver cancer and intrahepatic bile duct cancer would be diagnosed in the U.S. in 2024 (28,000 in men and 13,630 in women). It also projected about 29,840 deaths (19,120 men and 10,720 women). Hence, the growing frequency of liver cancer propels the unresectable hepatocellular carcinoma market's growth.
Get Your Unresectable Hepatocellular Carcinoma Market Report Here:
https://www.thebusinessresearchcompany.com/report/unresectable-hepatocellular-carcinoma-global-market-report
How will the growth rate of the unresectable hepatocellular carcinoma market shape industry trends by 2034?
In recent times, the market size for irreparable hepatocellular carcinoma has seen a slight increase. The market is projected to rise from $1.98 billion in 2024 to $2.01 billion in 2025, maintaining a compound annual growth rate (CAGR) of 1.9%. This growth experienced in the past can be credited to advancements in chemotherapy, outcomes of clinical trials, constraints of liver transplants, increased incidences of cancer, and wider access to treatments.
Expectations are high for robust growth in the market for unresectable hepatocellular carcinoma in the following few years. The market is set to inflate to a valuation of $2.95 billion in 2029, with a compound annual growth rate of 10.0%. Factors contributing to this anticipated growth during the forecast period include alterations in healthcare policies, tactics for patient stratification, the application of real-world evidence, patient advocacy and awareness, and economic dynamics. Key trends projected during the forecast period encompass precision medicine and biomarkers, the assimilation of real-world evidence and data, multidisciplinary methodologies, global clinical testings and partnerships, and patient-centric care.
Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12079&type=smp
What trends are poised to drive the future success of the unresectable hepatocellular carcinoma market?
The development of innovative products is a noteworthy trend being observed in the market of unresectable hepatocellular carcinoma. Major market contributors are resorting to these innovations to solidify their market stance. For instance, in October 2022, AstraZeneca, a biotechnology and pharmaceutical company from the UK, introduced its FDA-certified Imjudo (tremelimumab) in alliance with Imfinzi in the United States, targeting patients with unresectable hepatocellular carcinoma. The newly introduced treatment strategy, referred to as the STRIDE regimen (Single Tremelimumab Regular Interval Durvalumab), combines a single dose of the anti-CTLA-4 antibody Imjudo at 300mg with the anti-PD-L1 antibody Imfinzi at 1500 mg, to be administered every four weeks. The data indicated that patients treated with Imjudo and Imfinzi simultaneously had a mortality rate 22% lesser than those treated with sorafenib.
Which primary segments of the unresectable hepatocellular carcinoma market are driving growth and industry transformations?
The unresectable hepatocellular carcinoma market covered in this report is segmented -
1) By Type: Primary, Secondary, Benign Liver Growth
2) By Treatment Type: Chemotherapy, Molecularly Targeted Therapy, Immunotherapy, Other Treatments
3) By End-Users: Hospitals, Specialty Clinics, Cancer Centers
Subsegments:
1) By Primary: Hepatocellular Carcinoma (HCC), Fibrolamellar Carcinoma, Hepatoblastoma
2) By Secondary: Metastatic Liver Cancer, Intrahepatic Cholangiocarcinoma
3) By Benign Liver Growth: Hepatic Adenoma, Focal Nodular Hyperplasia, Hemangiomas
Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12079
Which geographical regions are pioneering growth in the unresectable hepatocellular carcinoma market?
North America was the largest region in the unresectable hepatocellular carcinoma market in 2024. The regions covered in the unresectable hepatocellular carcinoma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Who are the influential players reshaping the unresectable hepatocellular carcinoma market landscape?
Major companies operating in the unresectable hepatocellular carcinoma market include Pfizer Inc., Johnson & Johnson Private Limited, F Hoffmann-La Roche Ltd., Merck & Co Inc., Bayer AG, Bristol-Myers-Squibb Company, Astrazeneca PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc., Chugai Pharmaceutical Co Ltd., Eisai Co. Ltd., Ipsen S.A., Jiangsu HengRui Medicine Co. Ltd., Exelixis Inc., BeiGene Ltd., Halozyme Therapeutics Inc., Innovent Biologics Inc., Sirtex Medical Limited, Blueprint Medicines Corporation, Genentech Inc., CStone Pharmaceuticals, Pharmicell Co. Ltd., Pharmaxis Ltd., Delcath Systems Inc., Yiviva Inc., Celsion Corporation, Mendus AB.
Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=12079&type=smp
What Is Covered In The Unresectable Hepatocellular Carcinoma Global Market Report?
• Market Size Forecast: Examine the unresectable hepatocellular carcinoma market size across key regions, countries, product categories, and applications.
• Segmentation Insights: Identify and classify subsegments within the unresectable hepatocellular carcinoma market for a structured understanding.
• Key Players Overview: Analyze major players in the unresectable hepatocellular carcinoma market, including their market value, share, and competitive positioning.
• Growth Trends Exploration: Assess individual growth patterns and future opportunities in the unresectable hepatocellular carcinoma market.
• Segment Contributions: Evaluate how different segments drive overall growth in the unresectable hepatocellular carcinoma market.
• Growth Factors: Highlight key drivers and opportunities influencing the expansion of the unresectable hepatocellular carcinoma market.
• Industry Challenges: Identify potential risks and obstacles affecting the unresectable hepatocellular carcinoma market.
• Competitive Landscape: Review strategic developments in the unresectable hepatocellular carcinoma market, including expansions, agreements, and new product launches.
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Primary Catalyst Driving Unresectable Hepatocellular Carcinoma Market Share Evolution in 2025: The Rising Prevalence Of Liver Cancer Propels Growth In The Unresectable Hepatocellular Carcinoma Market Share Driver here
News-ID: 3897941 • Views: …
More Releases from The Business Research Company
Technological Advancements With App Based Subscription Programs Industry Trends …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Car Washing Service Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
In recent years, the car washing service market size has been expanding at a consistent rate. It is projected that from $30.1 billion in 2024, it will surge to $30.75 billion in 2025, with…
Major Growth Driver Identified in 2025 Well Intervention Market: Rising Energy D …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Well Intervention Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The size of the well intervention market has seen consistent growth over the past few years. The market, which will increase from $9.39 billion in 2024 to $9.84 billion in 2025 at a compound annual…
Growing E-Commerce Sector Fuels Demand For Telephone Call Centers: Critical Driv …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Telephone Call Centers Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market for telephone call centers has seen a slight rise in recent years. The market value is predicted to increase from $136.61 billion in 2024 to $138.62 billion in 2025, maintaining a compound…
Private Household Services Market Expansion Continues, with Forecast Valuation o …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Private Household Services Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
There has been a significant expansion in the private household services market size in the past few years. This market will see an escalation from $321.58 billion in 2024 to $351.99 billion in 2025,…
More Releases for Carcinoma
Rising Occurrence Of Hepatocellular Carcinoma Fuels Growth In The Hepatocellular …
The Hepatocellular Carcinoma Drugs Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Hepatocellular Carcinoma Drugs Market Size During the Forecast Period?
The Hepatocellular Carcinoma Drugs Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025…
Major Market Shift in Urothelial Carcinoma Treatment Industry: Innovations In Ur …
What Is the Forecasted Market Size and Growth Rate for the Urothelial Carcinoma Treatment Market?
In the recent years, there has been a swift escalation in the size of the urothelial carcinoma treatment market. It is projected to expand from $2.86 billion in 2024 to $3.37 billion in 2025, boasting a Compound Annual Growth Rate (CAGR) of 18.0%. The growth during the past period can be credited to an upsurge in…
Hepatocellular Carcinoma Pipeline 2024
DelveInsight, "Hepatocellular Carcinoma Pipeline Insight 2024" report provides comprehensive insights about 90+ companies and 95+ pipeline drugs in Hepatocellular Carcinoma pipeline landscape. It covers the Hepatocellular Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hepatocellular Carcinoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Request a sample and discover the recent…
Urothelial Carcinoma Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Urothelial Carcinoma Pipeline Insight 2024" report provides comprehensive insights about 40+ Urothelial Carcinoma companies and 50+ pipeline drugs in the Urothelial Carcinoma pipeline landscape. It covers the Urothelial Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Urothelial Carcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways…
Urothelial Carcinoma Pipeline Insights Report 2024
DelveInsight's, "Urothelial Carcinoma Pipeline Insight 2024" report provides comprehensive insights about 40+ Urothelial Carcinoma companies and 50+ pipeline drugs in the Urothelial Carcinoma pipeline landscape. It covers the Urothelial Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Urothelial Carcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways…
Nasopharyngeal Carcinoma Treatment Market
The latest Report Available at USD Analytics Market, "Nasopharyngeal Carcinoma Treatment Market" provides a pin-point analysis of changing competitive dynamics and a forward-looking perspective on different factors driving or restraining industry growth.
As the Political, Economic, Social, Technological, Environmental, and Legal factors continue to change, business leaders across industries have shifted focus to strategic objectives to achieve market excellence. The "Global Nasopharyngeal Carcinoma Treatment Market Size, Share Analysis with Forecast to…
